17
1. 9. 2015.
Adalimumab in the treatment of moderate‐to‐severe chronic plaque psoriasis in patients switching from other biologics
Ample evidence shows that switching from one biological agent to another may prove effective when response to the first one is inadequate. Nevertheless, there are little data so far showing the efficacy and safety of adalimumab in patients with plaque psoriasis who previously received another biologic agent.